8-K: Vera Therapeutics Anticipates Key Data Readout for IgAN Treatment, Eyes Potential FDA Submission

Vera Therapeutics reports Q1 2025 financial results and remains on track to announce pivotal Phase 3 trial results for atacicept in IgAN, with potential FDA submission planned for Q4 2025.

Summary

• Vera Therapeutics announced its Q1 2025 financial results and provided a business update.
• The company is on track to announce primary endpoint results from the pivotal Phase 3 ORIGIN trial of atacicept in IgAN in Q2 2025.
• Vera plans to submit a Biologics License Application (BLA) to the FDA for atacicept accelerated approval in IgAN in Q4 2025, potentially leading to a commercial launch in 2026.
• The company has expanded the atacicept development program to include other autoimmune kidney diseases like PMN, FSGS, and MCD.
• Vera acquired exclusive rights to VT-109, a novel fusion protein targeting BAFF and APRIL.
• The net loss for Q1 2025 was $51.7 million, or $0.81 per share, compared to a net loss of $28.4 million, or $0.56 per share, for Q1 2024.
• Net cash used in operating activities was $54.4 million for Q1 2025, compared to $33.8 million for the same period last year.
• Vera reported $589.8 million in cash, cash equivalents, and marketable securities as of March 31, 2025, sufficient to fund operations through potential approval and U.S. commercial launch of atacicept.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company is on track with its key clinical trial and regulatory milestones, and has sufficient cash to fund operations through potential commercial launch. However, the increased net loss and cash usage are concerning.

Positives

• Vera is on track to announce primary endpoint results for the Phase 3 ORIGIN trial in Q2 2025.
• The company plans to submit a BLA for atacicept in Q4 2025, potentially leading to a commercial launch in 2026.
• Vera has expanded its atacicept development program to include multiple autoimmune kidney diseases.
• The company acquired rights to VT-109, a novel fusion protein.
• Vera has sufficient cash to fund operations through potential approval and commercial launch of atacicept.

Negatives

• The net loss for Q1 2025 was $51.7 million, higher than the $28.4 million loss in Q1 2024.
• Net cash used in operating activities increased to $54.4 million in Q1 2025 from $33.8 million in Q1 2024.

Risks

• The success of the BLA submission and potential FDA approval for atacicept are subject to regulatory risks.
• Clinical trial results may differ from earlier trials, and preliminary results may not be predictive of topline results.
• Macroeconomic and geopolitical events could impact the business.
• The company's ability to successfully develop and commercialize atacicept and VT-109 is subject to various risks and uncertainties.

Future Outlook

Vera Therapeutics anticipates announcing primary endpoint results from the Phase 3 ORIGIN trial in Q2 2025 and plans to submit a BLA to the FDA in Q4 2025, potentially leading to a commercial launch in 2026. The company believes it has sufficient cash to fund operations through potential approval and U.S. commercial launch of atacicept.

Management Comments

• Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics, stated that the company is rapidly approaching a significant milestone with the upcoming primary endpoint results from the pivotal atacicept ORIGIN 3 trial.
• Fordyce believes that if successful, this will enable a BLA submission to the FDA in the second half of this year, which may allow approval and commercial launch in 2026.
• Fordyce also stated that atacicept has the potential to advance the standard of care in IgA nephropathy if approved.
• The Vera team is well-positioned to build on the success of the lead atacicept development program in IgAN, with the expansion into additional potential indications in other autoimmune kidney diseases and beyond.

Industry Context

Vera Therapeutics is focused on developing treatments for immunological diseases, specifically IgAN and other autoimmune kidney diseases. The company's lead product candidate, atacicept, targets B cells to reduce autoantibodies. The development of VT-109, a novel fusion protein targeting BAFF and APRIL, further expands the company's potential in treating B cell mediated diseases. The IgAN market is an area of unmet need, and successful development and commercialization of atacicept could position Vera as a key player in this space.

Comparison to Industry Standards

• Atacicept is being developed for IgAN, a disease with limited treatment options, competing with companies like Calliditas Therapeutics (Tarpeyo) and Omeros Corporation (Narsoplimab).
• The Phase 2b ORIGIN clinical trial of atacicept in IgAN met its primary and key secondary endpoints, with statistically significant and clinically meaningful proteinuria reductions and stabilization of eGFR versus placebo through 36 weeks, which is a competitive result.
• The expansion of atacicept development into other autoimmune kidney diseases like PMN, FSGS, and MCD positions Vera to compete with companies like Retrophin (sparsentan) and Travere Therapeutics (focal segmental glomerulosclerosis (FSGS)).
• The acquisition of VT-109, a novel fusion protein targeting BAFF and APRIL, positions Vera to compete with companies like Bristol Myers Squibb (belimumab) and GlaxoSmithKline (Benlysta) in the broader B cell mediated diseases market.

Stakeholder Impact

• Positive impact on patients with IgAN and other autoimmune kidney diseases if atacicept is approved.
• Potential positive impact on shareholders if the company achieves its clinical and regulatory milestones.
• Potential positive impact on employees through continued growth and development of the company.

Next Steps

• Announcement of primary endpoint results from the pivotal ORIGIN Phase 3 trial in IgAN in Q2 2025.
• Submission of a Biologics License Application (BLA) for atacicept in IgAN to the U.S. FDA in Q4 2025 for accelerated approval.
• Potential PDUFA date and commercial launch in 2026.
• Continued enrollment in the ORIGIN EXTEND study.
• Further development of atacicept across multiple autoimmune kidney diseases.
• Advancement of VT-109 development program.

Key Dates

Keywords

atacicept, IgA Nephropathy, IgAN, VT-109, autoimmune kidney diseases, Phase 3 trial, BLA submission, FDA, Vera Therapeutics, financial results